The Influence of Enhanced External Counterpulsation Intervention on the Biomechanical Stress Distribution of Advanced Plaque: A 3D FSI Study Based on in vivo Animal Experiment
Enhanced external counterpulsation (EECP) is an effective therapy to provide beneficial assistance for the failing heart by reducing cardiac afterload and increasing blood flow perfusion noninvasively. The technique of EECP involves the use of the EECP device to inflate and deflate a series of compression cuffs wrapped around the patient’s calves, lower thighs, and upper thighs. As the result, the enhanced flow perfusion is derived from the device’s propelling blood from veins of lower body to arteries of upper body and increases the blood supply for the important organs and brain.
In the ACCF/AHA Guideline and ESC Guideline on the management of stable ischemic heart disease and coronary artery disease, EECP has been given a Class IIb and Class IIa recommendation respectively. In the ASA Guideline on the early management of Acute Ischemic stroke, EECP has been given a Class IIa recommendation.
However, considering that EECP performance significantly elevates the acute blood pressure level as well as the perfusion level in systemic arterial tree and in diastolic, whether it will increase the risk of hypertension-related events such as atherosclerotic plaque rupture causes great concern in its clinical applications. But, the influence of EECP intervention on plaque progression remains elusive to this day and need to be assessed.
It is generally agreed that biomechanical stresses play important roles in advanced atherosclerotic plaque progression and rupture. We hypothesized that EECP may intervene the advanced plaque progression via induced the variation of mechanical stresses in plaques.
In this present paper, a pilot study containing animal experiment and numerical simulation was conducted to quantify the variations of biomechanical stresses of the plaque during EECP intervention. An experimentally induced hypercholesterolemic porcine model was developed and the basic hemodynamic measurements were performed in vivo before and during EECP intervention. Meanwhile, 3D multi-component idealized models with fluid-structure interactions (FSI) for carotid atherosclerotic plaques were introduced to solve the wall shear stress (WSS) and plaque structural stress (PWS) before and during intervention. Three cases of fibrous cap thickness (FC=600, 200 and 65μm) and three cases of material properties of the plaque components (normal, hard and soft) were involved in the current study.
Numerical results showed that the max WSS level at the throat of the plaque, the 3D critical plaque wall stress (3D CPWS) level at the fibrous cap and the global max plaque wall stress (GMPWS) level at the shoulder of the plaque were all significantly augmented during EECP. When FC=65μm, EECP intervention augmented 118.1%±1.1% of the Max WSS level, 15.56%±1.68% of the 3D CPWS level and 14.78%±0.24% of the GMPWS level comparing to situations without EECP intervention.
Considering that blood flow shear stress and structural stress are indexes that are presently thought might contribute to advanced plaque progression and its final rupture, our pilot study thus suggests that EECP treatment may intervene the plaque progression by elevating the levels of these indexes. But whether EECP treatment will increase the risk of plaque rupture and should be taken into account in its patient selection need a further detailed study and follow-up observation.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All authors should sign the copyright agreement by downloading the file at
Manuscript reference number:
Mailing address and Telephone/Fax numbers:
Each author must read and sign the following statements.
RETAINED RIGHTS: Except for copyright, other proprietary rights related to the work shall be retained by the authors. To reproduce any text, figures, tables, or illustrations from this work in future works of their own, the authors must obtain written permission from Tech Science Press. ORIGINALITY: Each author warrants that the submission to the work is original. Neither this work has been already published nor shall be submitted for publication elsewhere while under consideration for the publication by this journal.
AUTHORSHIP RESPONSIBILITY: Each author certifies that he or she has participated sufficiently in the preparation of the present work to take public responsibility for it. Each has reviewed the final version of the work, believes it is a valid work and approves it for publication. Moreover, they should produce data upon which the work is based if requested by the Editors of the journal.
DISCLAIMER: Each author warrants that this work contains no libelous or unlawful statements and does not infringe on the rights of others. If excerpts (text, figures, tables, or illustrations) from copyrighted works are included, a written release will be secured by the authors prior to submission, and credit to the original publication will be properly acknowledged. Each author warrants that he or she has obtained, prior to submission, written releases from patients whose names or photographs are submitted as part of the work.
TRANSFER OF COPYRIGHT
AUTHORS’ OWN WORK: In consideration of Tech Science Press’s publication of the work, the authors hereby transfer, assign, and otherwise convey all copyright ownership worldwide, in all languages, and in all forms of media now or hereafter known, including electronic media such as CD-ROM, Internet, and Intranet, to Tech Science Press. If Tech Science Press should decide for any reason not to publish an author’s submission to the work, Tech Science Press shall give prompt notice of its decision to the corresponding author, this agreement shall terminate, and neither the author nor Tech Science Press shall be under any further liability or obligation. The authors grant Tech Science Press the rights to use their names and biographical data (including professional affiliation) in the work and in its or the publication’s promotion.
FINANCIAL DISCLOSURE: Each author certifies that he or she has no commercial associations that might pose a conflict of interest in connection with the submitted article, except as disclosed in a separate attachment. All funding sources supporting the work and all institutional or corporate affiliations of the authors are acknowledged in a footnote in the work.
INSTITUTIONAL REVIEW BOARD/ANIMAL CARE COMMITTEE APPROVAL: Each author certifies that his or her institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.
I certify that the above article has been written in the course of the author’s employment by the United States Government, so that it is not subject to U.S. copyright laws, or that it has been written in the course of the author’s employment by the United Kingdom Government (Crown Copyright).
Note to U.S. Government Employees:
If the above article was not prepared as part of the employee’s duties, it is not a U.S. Government work. If the above article was prepared jointly, and any co-author is not a U.S. Government employee, it is not a U.S. Government work.